These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38741507)

  • 21. Dermatomyositis: An Update on Diagnosis and Treatment.
    Cobos GA; Femia A; Vleugels RA
    Am J Clin Dermatol; 2020 Jun; 21(3):339-353. PubMed ID: 32096127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.
    Suzuki Y; Hayakawa H; Miwa S; Shirai M; Fujii M; Gemma H; Suda T; Chida K
    Lung; 2009; 187(3):201-6. PubMed ID: 19387736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the clinical management of juvenile dermatomyositis.
    Huber AM
    Expert Rev Clin Immunol; 2018 Dec; 14(12):1021-1028. PubMed ID: 30308133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case].
    Girard C; Vincent T; Bessis D
    Ann Dermatol Venereol; 2013 Oct; 140(10):628-34. PubMed ID: 24090894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.
    Hirakata M
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Dec; 30(6):444-54. PubMed ID: 18174673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of Dermatomyositis and Immune-Mediated Necrotizing Myopathy with Poor Muscle Recovery with Steroids and IVIg: Therapeutic Strategies for Refractory Inflammatory Myositis].
    Tomimitsu H
    Brain Nerve; 2022 May; 74(5):545-552. PubMed ID: 35589645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Juvenile Dermatomyositis: An Update.
    Papadopoulou C; Wedderburn LR
    Paediatr Drugs; 2017 Oct; 19(5):423-434. PubMed ID: 28550457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of cutaneous dermatomyositis: current therapeutic options.
    Quain RD; Werth VP
    Am J Clin Dermatol; 2006; 7(6):341-51. PubMed ID: 17173468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dermatomyositis and polymyositis: clinical aspects and treatment].
    Hachulla E
    Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of polymyositis and dermatomyositis.
    Marie I; Mouthon L
    Autoimmun Rev; 2011 Nov; 11(1):6-13. PubMed ID: 21740984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Idiopathic inflammatory myopathies].
    Vencovský J
    Vnitr Lek; 2018; 64(2):155-163. PubMed ID: 29595280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of autoimmune inflammatory myopathies.
    Mastaglia FL
    Curr Opin Neurol; 2000 Oct; 13(5):507-9. PubMed ID: 11073355
    [No Abstract]   [Full Text] [Related]  

  • 33. Dermatomyositis: Diagnosis and treatment.
    Waldman R; DeWane ME; Lu J
    J Am Acad Dermatol; 2020 Feb; 82(2):283-296. PubMed ID: 31279813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous signs of classical dermatomyositis.
    Auriemma M; Capo A; Meogrossi G; Amerio P
    G Ital Dermatol Venereol; 2014 Oct; 149(5):505-17. PubMed ID: 25014587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
    Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
    Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
    [No Abstract]   [Full Text] [Related]  

  • 37. Current approach to the treatment of polymyositis and dermatomyositis.
    Oddis CV
    Curr Opin Rheumatol; 2000 Nov; 12(6):492-7. PubMed ID: 11092197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
    Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
    Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyopathic dermatomyositis presenting as skin necrosis.
    Veetil BM; Whitt I
    J Clin Rheumatol; 2011 Sep; 17(6):332-3. PubMed ID: 21869704
    [No Abstract]   [Full Text] [Related]  

  • 40. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study.
    Shimojima Y; Ishii W; Matsuda M; Tazawa K; Ikeda S
    BMC Musculoskelet Disord; 2012 Nov; 13():228. PubMed ID: 23173570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.